(ACTH) for the Treatment of Sarcoid Uveitis

ClinicalTrials.gov ID: NCT03473964

Public ClinicalTrials.gov record NCT03473964. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Adrenocorticotrophic Hormone (ACTH) for the Treatment of Sarcoid Uveitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Sarcoidosis is a multisystem granulomatous disease that can affect nearly any organ in the body. While most commonly affecting the lungs, vision threatening eye involvement occurs in approximately 25% of patients with sarcoid. Eye involvement may lead to a chronic, sight-threatening uveitis which may result in cataract, glaucoma, and macular edema. The treatment of sarcoid uveitis involves the use of topical and systemic corticosteroids or potent immunosuppressive agents (medications that suppress the body's immune system) both of which can cause severe long-term side effects. The adverse effects of steroids may be avoided by treatment with the use as H.P. Acthar® Gel. The effectiveness of H.P. Acthar® Gel in the treatment of sarcoid uveitis and patient quality of live have not been previously examined. These issues, will be explored in this research.

Study identification

NCT ID: NCT03473964
Recruitment status: Not listed
Study type: Observational
Phase: Not listed
Lead sponsor: John Huang, MD; Other
Enrollment: 10 participants

Conditions and interventions

Conditions

Sarcoid Uveitis

Interventions

H.P. Acthar gel Drug

Drug

Eligibility (public fields only)

Age range: Not listed
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2018
Primary completion: Feb 28, 2019
Completion: Dec 31, 2019
Last update posted: Mar 21, 2018

2018 – 2020

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
New England Retina Associates	Hamden	Connecticut	06518	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03473964, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 21, 2018 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03473964 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →